<DOC>
	<DOCNO>NCT01223690</DOCNO>
	<brief_summary>The herein protocol base result one former clinical trial conduct study group show considerable efficacy intravenously administer clarithromycin adjuvant antimicrobial chemotherapy patient sepsis , septic shock respiratory failure field ventilator-associated pneumonia . The proposed clinical trial base need generalize application intravenous clarithromycin total admit septic patient irrespective underlying cause sepsis .</brief_summary>
	<brief_title>Clarithromycin Immunomodulator Management Sepsis</brief_title>
	<detailed_description>The idea application intravenous clarithromycin immunomodulatory therapy management sepsis evolve vitro result show concentration close 10μg/ml may refrain biosynthesis pro-inflammatory cytokine inhibit activation translation factor NF-κB . Intravenously administer clarithromycin widely apply experimental sepsis one susceptible isolate Escherichia coli , one multidrug-resistant isolate Pseudomonas aeruginosa one pan-resistant isolate Klebsiella pneumoniae induction pyelonephritis test isolates . Results animal study reveal clarithromycin inhibit evolution systemic inflammatory response syndrome ( SIRS ) act cellular level blood monocyte effect express administer induction sepsis . Based latter experimental data , one double-blind randomize clinical trail conduct period June 2004-December 2005 4th Department Internal Medicine , 1st Department Critical Care 2nd Department Critical Care University Athens . The study enrol 200 subject ventilator-associated pneumonia ( VAP ) sepsis , severe sepsis septic shock ; 100 receive placebo 100 clarithromycin . Statistical analysis result reveal clarithromycin effect early resolution sign sepsis VAP accompany ) prolongation survival total patient first 16 day follow-up , b ) prolongation survival patient septic shock 28 day follow-up , c ) 2.75-fold reduction relative risk death first 28 day follow-up patient multiple organ failure . The proposed clinical trial base extremely beneficial result clarithromycin septic population patient VAP create follow need : ) generalize application intravenous clarithromycin total admit septic patient irrespective underlying cause sepsis , b ) expand effect clarithromycin great time period first 19 day post start administration .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>One follow infection : ) primary secondary bacteremia Gramnegative bacteria , b ) acute pyelonephritis , c ) intrabdominal infection . Only one episode infection per patient enrol . Both patient communityacquired nosocomial infection eligible study . The presence least two follow criterion sepsis accord ACCP/SCCM ( 8 ) ) body temperature &gt; 38 degreesC &lt; 36 degreesC ; b ) pulse rate &gt; 90/min ; c ) breath rate &gt; 20/min Pco2 &lt; 32mmHg ; and/or ) leukocytosis ( white blood cell count &gt; 12,000/μl ) leukopenia ( white blood cell count &lt; 4,000/μl ) &gt; 10 % band form Presence HIV infection Intake corticosteroid dose equal 1mg/kg equivalent prednisone one month Neutropenia &lt; 500 neutrophils/μl Selection attend physician macrolide empiric antimicrobial therapy infection make patient eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>sepsis</keyword>
	<keyword>infection</keyword>
	<keyword>bacteremia</keyword>
	<keyword>clarithromycin</keyword>
</DOC>